Landmark Study Demonstrates Sustained Clinical Benefits of Flexitouch Plus as First-Line Therapy in Treating Head and Neck Cancer-Related Lymphedema
October 28, 2025 16:05 ET | Source: Tactile Systems Technology, Inc. MINNEAPOLIS,…
LUMOSA THERAPEUTICS ANNOUNCES POSITIVE RESULTS FROM LT3001(INTRAVENOUS ODATROLTIDE) PHASE 2B CLINICAL TRIAL IN ACUTE ISCHEMIC STROKE
Results presented at the 17th World Stroke Congress (WSC 2025) LT3001(Odatroltide)-202 phase…
Elixir Medical Announces Significant Late Breaking Clinical Results for DynamX Bioadaptor Demonstrating Nearly 50% Reduction in Coronary Event Rates vs. Current PCI Standard of Care
Results were presented at the Transcatheter Cardiovascular Therapeutics (TCT) Conference 2025 in…
Cullinan Therapeutics Shares Additional Preclinical B Cell Depletion Data for CLN-978, Supporting Clinical Development Across Multiple Autoimmune Diseases, at ACR Convergence 2025
October 25, 2025 11:01 ET | Source: Cullinan Therapeutics, Inc. CLN-978 led…
New Clinical Data Confirms Yomi Robotic System Enhances Efficiency in Dental Implant Surgery
October 23, 2025 13:48 ET | Source: Neocis MIAMI, Oct. 23, 2025…
SpringWorks Therapeutics Announces Publication of Long-Term Efficacy and Safety Data from the Phase 3 DeFi Trial of OGSIVEO (nirogacestat) in Adults with Desmoid Tumors in the Journal of Clinical Oncology
Long-term continuous OGSIVEO treatment for up to 4 years was associated with…
RAPT Therapeutics to Report Topline Data from Phase 2 Clinical Trial of RPT904 in Chronic Spontaneous Urticaria (CSU)
October 19, 2025 08:00 ET | Source: RAPT Therapeutics, Inc. SOUTH SAN…
Junshi Biosciences Announces FDAs Approval of IND Application for Phase 2/3 Clinical Study of JS207 for the Neoadjuvant Treatment of NSCLC Patients
SHANGHAI, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd…
Curium Group, PeptiDream and PDRadiopharma Enroll First Patient to Registrational Clinical Trial of64Cu-PSMA-I&T for Prostate Cancer in Japan
PARIS, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Curium Group announced today that…
Quanta Therapeutics Announces First Clinical Data Presentation for QTX3034, an Oral G12D-Preferring Multi-KRAS Inhibitor, at 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
RADNOR, Pa. and SOUTH SAN FRANCISCO, Calif., Oct. 13, 2025 (GLOBE NEWSWIRE)…
